We thank Pruthi and Liss for their excellent News and Views commentary (Prophylactic antibiotic for prostate biopsy: the carb a penem gamble. Nat. Rev. Urol. 14, 394-396 (2017)) which discusses our recent paper on ertapenem prophylaxis for transrectal ultrasonographyguided prostate biopsy (TRUPB) 1, 2 . We share their concerns regard ing the generation of antimicrobial resist ance -indeed, this worry was the reason for performing our study -and agree that inappropriate broadspectrum antibiotic use should be avoided to preserve them for the future.
To add to their discussion, we find it surprising that ciprofloxacin has remained the recommended antibiotic prophylaxis for TRUPB by the American Urological Association and the European Association of Urology in the face of steadily rising fluoro quinolone resistance [3] [4] [5] [6] . Evidently, genera tion of resistance seems to not have been of sufficient concern to result in changes to this recommendation. We are not aware of any studies analogous to ours that provide any degree of reassurance regarding the collateral damage caused by ciprofloxacin prophy laxis. Canadian guidelines recommend that antibiotic choices should be made on the basis of local data, but do not provide a clear recommendation 7 . An assumption seems to be widely held, including by Pruthi and Liss, that carba penems pose a greater risk than fluoro quinolones for the development of clinically relevant antibiotic resistance. We have demon strated in our population that erta penem prophylaxis does not drive carbapenem resist ance, and several studies suggest that the use of fluoroquinolones poses a greater risk [8] [9] [10] . We acknowledge that in populations with higher levels of carbapenem resistance erta penem prophylaxis might carry an unknown risk, but we argue that the 'ciprofloxacin gamble' is high risk, has already failed, and alternative options must be sought.
